In 2005, the first GLP-1 receptor agonist received FDA approval in the U.S
In a recent clinical study, individuals with heart failure and preserved ejection fraction who received weekly semaglutide injections (2.4 mg) for 52 weeks experienced substantially improved symptoms and physical function compared to the placebo group 9
Exendin-4 inhibits interleukin-1beta-induced iNOS expression at the protein level, but not at the transcriptional and posttranscriptional levels, in RINm5F beta-cells
Relationships between gastric emptying, postprandial glycemia, and incretin hormones
Watch our video series to learn how DPP-4 complicates measuring GLP-1 accurately and how to properly handle GLP-1 samples for more accurate results
Biopharma PEG supplies polyethylene glycol (PEG) derivatives, monodisperse PEGs, custom PEG derivative synthesis and PEGylation services worldwide, from R&D through GMP commercial quantities, for preclinical, clinical trials, and commercial products for pharma, biotech, medical devices, and diagnostics